TEXT-S&P rates BioMarin Pharmaceutical notes
News | 11 June 2012
June 11 - Overview -- US biotechnology company BioMarin Pharmaceutical Inc. completed an equity offering that raised $250 million, more than doubling its cash balance, extending its ability to fund research by about one year.
Click on the link to read the full article at Reuters
(This link will open in a new window)
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
